AroCell AB: announces that a distribution agreement has been signed with Pathway Diagnostics Ltd, for distribution of the AroCell TK 210 ELISA test in United Kingdom and Ireland.
13 oct. 2017 02h50 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
"We very much look forward to...
AroCell AB: AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK National Cancer Research Institute (NCRI) Annual Meeting November 2017
26 sept. 2017 05h00 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
AroCell AB (publ) announces today that a...
AroCell AB: TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium
22 sept. 2017 05h30 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
AroCell AB (publ) announces today that an...
AroCell AB: New application for AroCell TK 210 ELISA opens new opportunities for drug development research
18 sept. 2017 08h15 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Uppsala September 18,...
AroCell AB: Interim report, Q2 2017
24 août 2017 02h15 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
AroCell AB (publ) Reporting period...
Beslut vid årsstämman i AroCell AB (publ) 2017
18 mai 2017 12h30 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
PRESSMEDDELANDE 18 MAJ 2017 Beslut...
AroCell (publ): Interim report for period 1 January - 31 March 2017
11 mai 2017 02h25 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
AroCell AB (publ) Interim...
AroCell AB: KALLELSE TILL ÅRSSTÄMMA I AROCELL AB (PUBL)
13 avr. 2017 05h00 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
...
AroCell AB: (publ) Year-End Report
16 févr. 2017 02h15 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Report for period 1 January - 31 December...
AroCell AB: Research poster on prostate cancer has been accepted by the American Association for Cancer Research (AARC)
24 janv. 2017 05h45 HE
|
AroCell AB
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
AroCell AB (publ) announces today that a research...